Answers are grounded in this paper and cite their sources.
PD-1 or PD-L1 blockade therapy is a preferable treatment option over conventional therapy for both patients that are PD-L1 positive and PD-L1 negative. This finding suggests that PD-L1 expression status alone is insufficient in determining which patients should be offered PD-1 or PD-L1 blockade therapy.
No takes yet. Share an insight, caveat, or question.
Shen et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: